BioCentury | Apr 3, 2020
Distillery Therapeutics

Targeting CD36 for melanoma and colorectal cancer

...defining the therapeutic potential of CD36 in patient samples. Arteria S.A. has the CD36 inhibitor AP-5258...
BioCentury | Mar 5, 2015
Distillery Therapeutics

Therapeutics: CD36 (GPIV); macrophage scavenger receptor 1 (MSR-1; SR-A; CD204)

...whether the nanoparticles reduce cardiovascular events in atheroscleroic models. Arteria S.A. has the CD36 inhibitor AP-5258...
BioCentury | Dec 12, 2013
Distillery Therapeutics

Indication: Infectious disease

...Next steps include identifying a humanized antibody against CD36. Arteria S.A. has the CD36 inhibitor AP-5258...
BioCentury | Feb 21, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) CD36 (GPIV) Mouse studies suggest antagonizing CD36 could help treat cerebral amyloid angiopathy. Symptoms of cerebral amyloid angiopathy...
BioCentury | Nov 14, 2011
Clinical News

Arteria preclinical data

...In mice and rats, oral AP-5258 significantly inhibited the transfer of postprandial triglycerides vs. an inactive...
...I trial of the CD36 (GPIV) inhibitor next year. Arteria S.A. , Caissargues, France Product: AP-5258...
Items per page:
1 - 5 of 5